I like this stock. It has formed a inverse H&S. OBV and MACD both look good. I think you could ride this one all the way into overhead resistance around $40. If it breaks thru resistance you it could skyrocket. If it does not break thru resistance, no worries you will have made you profit.
Daily
Notice the macd has formed...
ACOR just started to make upward run. It got good moneyflow accumulation. Overall looks very good long setup.
* Trade Criteria *
Date First Found- June 20, 2017
Pattern/Why- Breakout Momentum Long
Entry Target Criteria- Break of $18.03
Exit Target Criteria- $19.83
Stop Loss Criteria- $17.06
Please check back for Trade updates. (Note: Trade update is...
acor sits at a support level of 28.5 where price shows indecision
its now a mather of how this resolves itself a breakout to the downside
will most likley yield into a broken support and therefore a further decline
*however if someone is buying into that breakout (fade it) we may reside in the range
and reject support for the time beeing (fakeout)
ACOR has declined down to the 300-day moving average. Today it completed a double bottom, bouncing off the moving average while MACD's blue line has crossed the slow moving average. Stop loss will trigger only on a CLOSE below today's candlestick low, and it may convert into a trailing stop, using either the 12 or 60-day MA.
Notes on the chart..if you decide to take a trade make your stop loss at recent swing low and target price noted on the chart. Checkout our site if you are interested in real time alerts www.2waytrading.com
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
ACOR
